KHCM
CRBU icon

Kettle Hill Capital Management’s Caribou Biosciences CRBU Stock Holding History

Kettle Hill Capital Management’s Portfolio CRBU Stock Details CRBU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-37,200
Closed -$392K – 55
2022
Q3 		$392K Buy
+37,200
New +$347K 0.09% 56

Other funds holding CRBU

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
RCMU
Rokos Capital Management (UK) London, United Kingdom $13.2B AUM 85.71% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
EWM
Elmwood Wealth Management Berkeley, California $400M AUM 17.81% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Kettle Hill Capital Management's CRBU Position: Q4 2022 in Review

Kettle Hill Capital Management sold out of Caribou Biosciences (CRBU) in Q4 2022, closing a stake of 37,200 shares — an estimated $392K sold.

Kettle Hill Capital Management first reported a position in CRBU in Q3 2022 and held it in 1 quarter. The position peaked at $392K in Q3 2022. 133 funds tracked by Wall St. Rank hold CRBU as of Q4 2022.

  • Kettle Hill Capital Management reported no remaining Caribou Biosciences position as of Q4 2022 after selling out during the quarter.
  • Kettle Hill Capital Management sold 37,200 Caribou Biosciences shares in Q4 2022, an estimated $392K.
  • Kettle Hill Capital Management first reported a position in Caribou Biosciences in Q3 2022 and held it in 1 quarter.
  • Kettle Hill Capital Management's Caribou Biosciences position peaked at $392K in Q3 2022.
  • 133 funds tracked by Wall St. Rank held Caribou Biosciences as of Q4 2022.

Based on Kettle Hill Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.